A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial



Offner, Fritz, Robak, Tadeusz, Janssens, Ann, Babu, K Govind, Kloczko, Janusz, Grosicki, Sebastian, Mayer, Jiri, Panagiotidis, Panagiotis, Schuh, Anna, Pettitt, Andrew
et al (show 5 more authors) (2020) A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. BRITISH JOURNAL OF HAEMATOLOGY, 190 (5). 736 - 740.

[img] Text
Minor revision_COMPLEMENT 1 Short report_March 6.docx - Accepted Version

Download (106kB)
[img] Text
Combined image_OS and PFS for BJH.pdf - Accepted Version

Download (33kB) | Preview
Item Type: Article
Uncontrolled Keywords: ofatumumab, chlorambucil, Complement 1, anti-CD20 monoclonal antibodies, chronic lymphocytic leukaemia
Depositing User: Symplectic Admin
Date Deposited: 10 Jun 2020 07:47
Last Modified: 25 Sep 2021 01:13
DOI: 10.1111/bjh.16625
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3089892